The Case for Expanding Access to GLP-1 Therapies
Recent findings presented at the European Association for the Study of Diabetes (EASD) annual meeting have sparked a significant conversation regarding the clinical use of GLP-1 receptor agonists, such as semaglutide and tirzepatide. Traditionally, these medications have been prescribed primarily for weight management in individuals with a BMI of 30 or higher, or those with a BMI of 27 accompanied by weight-related comorbidities like hypertension or type 2 diabetes. However, new research suggests that this criteria may leave a vulnerable population behind.
Dr. Karen Hvid of Copenhagen University Hospital and her research team have identified that individuals within the 'overweight' category—specifically those with a BMI between 25 and 26.9—are currently ineligible for these treatments despite facing substantial cardiovascular risks. The study posits that a significant portion of this group possesses physiological markers that mirror the health profiles of currently eligible candidates, suggesting that the current threshold for intervention may need to be re-evaluated to improve long-term heart health outcomes.
Analyzing the Data: UK Biobank and CGPS Findings
To investigate this, researchers utilized two massive datasets: the UK Biobank and the Copenhagen General Population Study (CGPS). The study tracked 313,145 individuals for over a decade, focusing on participants who were free of diabetes and coronary heart disease at the outset. By examining the incidence of heart attacks, surgical interventions, and cardiovascular-related deaths, the team was able to draw a direct comparison between currently eligible patients and those in the 'overweight' range who fall below the current prescription threshold.
The data revealed a striking overlap in health outcomes. Specifically, nearly 50% of the individuals in the 25–26.9 BMI range exhibited either elevated remnant cholesterol levels, chronic low-grade inflammation, or both. These biological markers are well-known precursors to coronary heart disease. When compared to the group already eligible for GLP-1 treatments, those with these specific markers in the lower BMI category showed a nearly identical risk profile for future cardiovascular events.
Why It Matters
- Redefining Risk: The study shifts the focus from simple weight metrics to metabolic markers like inflammation and remnant cholesterol.
- Preventative Potential: By treating these markers early with GLP-1 agonists, clinicians could theoretically prevent heart attacks and strokes in patients previously considered 'low risk' by BMI standards.
- Addressing the Gap: Roughly half of the BMI 25–26.9 cohort demonstrated risks similar to those in the higher BMI categories, representing a massive group currently excluded from therapeutic intervention.
Future Implications for Cardiology
The implications of these findings suggest a potential shift in how endocrinologists and cardiologists manage patient health. Because GLP-1 receptor agonists are known to lower both systemic inflammation and cholesterol levels, the study argues that they could serve as a powerful prophylactic tool against heart disease for a much broader demographic than previously understood.
While the study provides a compelling argument for broadening the indications for these drugs, the researchers emphasize that further clinical trials are necessary to confirm these observations. If future clinical trials validate these findings, medical guidelines could evolve to incorporate these biomarker-based criteria, potentially enabling millions of individuals to access life-saving heart protection earlier in their health journey. This move would signify a shift away from weight-centric prescribing toward a more nuanced, metabolic-focused approach to cardiovascular care.
